US2005100540A1PendingUtilityA1

Platelet-activating factor acetylhydrolase

56
Priority: Oct 6, 1993Filed: Aug 4, 2003Published: May 12, 2005
Est. expiryOct 6, 2013(expired)· nominal 20-yr term from priority
Inventors:Lawrence S. CousensChristine D. EberhardtPatrick GrayHai Le TrongLarry W. TjoelkerCheryl L. Wilder
A61P 9/10A61P 37/00A61P 9/00A61P 43/00A61P 31/04A61P 29/00A61P 15/06C12N 9/18A61P 11/06C07K 16/40A61P 11/02A61P 11/00A61P 17/00A61P 11/16A61P 15/00A61P 1/04A61K 38/00C07K 2317/24
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising PAF-AH enzyme and a pharmaceutically acceptable diluent, adjuvant or carrier.  
     
     
         2 . A method for treating a mammal susceptible to or suffering from a PAF-mediated pathological condition comprising administering the pharmaceutical composition of  claim 1  to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF in said mammal.  
     
     
         3 . A method for treating a mammal susceptible to or suffering from pleurisy comprising administering the pharmaceutical composition of  claim 1  to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF of said mammal.  
     
     
         4 . A method for treating a mammal susceptible to or suffering from asthma comprising administering the pharmaceutical composition of  claim 1  to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF of said mammal.  
     
     
         5 . A method for treating a mammal susceptible to or suffering from rhinitis comprising administering the pharmaceutical composition of  claim 1  to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF in said mammal.  
     
     
         6 . A method for treating a mammal susceptible to or suffering from necrotizing enterocolitis comprising administering the pharmaceutical composition of  claim 1  to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF in said mammal.  
     
     
         7 . A method for treating a mammal susceptible to or suffering from acute respiratory distress syndrome comprising administering the pharmaceutical composition of  claim 1  to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF in said mammal.

Join the waitlist — get patent alerts

Track US2005100540A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.